These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice. Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806 [TBL] [Abstract][Full Text] [Related]
7. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006 [TBL] [Abstract][Full Text] [Related]
8. SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes. Chen H; Birnbaum Y; Ye R; Yang HC; Bajaj M; Ye Y Cardiovasc Drugs Ther; 2022 Dec; 36(6):1091-1108. PubMed ID: 34448973 [TBL] [Abstract][Full Text] [Related]
9. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905 [TBL] [Abstract][Full Text] [Related]
10. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes. Davidson JA; Kuritzky L Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933 [TBL] [Abstract][Full Text] [Related]
11. SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice. Jurczak MJ; Saini S; Ioja S; Costa DK; Udeh N; Zhao X; Whaley JM; Kibbey RG Islets; 2018; 10(5):181-189. PubMed ID: 30118626 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation. Yang X; Liu Q; Li Y; Ding Y; Zhao Y; Tang Q; Wu T; Chen L; Pu S; Cheng S; Zhang J; Zhang Z; Huang Y; Li R; Zhao Y; Zou M; Shi X; Jiang W; Wang R; He J Br J Pharmacol; 2021 Apr; 178(8):1756-1771. PubMed ID: 33480065 [TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance. Tanday N; Irwin N; Flatt PR; Moffett RC Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307 [TBL] [Abstract][Full Text] [Related]
14. Novel frame-shift mutation in Slc5a2 encoding SGLT2 in a strain of senescence-accelerated mouse SAMP10. Unno K; Yamamoto H; Toda M; Hagiwara S; Iguchi K; Hoshino M; Takabayashi F; Hasegawa-Ishii S; Shimada A; Hosokawa M; Higuchi K; Mori M Biochem Biophys Res Commun; 2014 Nov; 454(1):89-94. PubMed ID: 25450362 [TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Vivian EM Drugs Context; 2014; 3():212264. PubMed ID: 25598831 [TBL] [Abstract][Full Text] [Related]
16. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice. Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371 [TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice. Cha JJ; Park HJ; Yoo JA; Ghee J; Cha DR; Kang YS Kidney Blood Press Res; 2024; 49(1):81-90. PubMed ID: 38185119 [TBL] [Abstract][Full Text] [Related]
18. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models. Yan PK; Zhang LN; Feng Y; Qu H; Qin L; Zhang LS; Leng Y Acta Pharmacol Sin; 2014 May; 35(5):613-24. PubMed ID: 24786232 [TBL] [Abstract][Full Text] [Related]
19. Improved glycemic control in mice lacking Sglt1 and Sglt2. Powell DR; DaCosta CM; Gay J; Ding ZM; Smith M; Greer J; Doree D; Jeter-Jones S; Mseeh F; Rodriguez LA; Harris A; Buhring L; Platt KA; Vogel P; Brommage R; Shadoan MK; Sands AT; Zambrowicz B Am J Physiol Endocrinol Metab; 2013 Jan; 304(2):E117-30. PubMed ID: 23149623 [TBL] [Abstract][Full Text] [Related]
20. Loss of function of renal Glut2 reverses hyperglycaemia and normalises body weight in mouse models of diabetes and obesity. de Souza Cordeiro LM; Bainbridge L; Devisetty N; McDougal DH; Peters DJM; Chhabra KH Diabetologia; 2022 Jun; 65(6):1032-1047. PubMed ID: 35290476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]